Combo of SGLT2 and ACE inhibitors reduces risk of cardiorenal complications: Circulation Medha Baranwal7 Dec 2022 7:30 PM ISTEmpagliflozin addition to ramipril, betters surrogate measures of kidney protection in patients with uncomplicated type 1 diabetes and preserved...
SGLT2i tied to lower mortality and better outcomes than DPP4i, finds Study Medha Baranwal7 Sept 2021 10:15 AM ISTItaly: Initiation of SGLT2 inhibitors under routine care versus initiation of DPP4 inhibitors leads to better cardiorenal outcomes and lower mortality...
Canagliflozin reduces risk of hyperkalemia in diabetics with CKD: Study Dr. Shravani Dali28 Aug 2021 9:00 AM ISTThe use of canagliflozin reduces the risk of hyperkalaemia in people with type-2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) without...
SGLT2 inhibitors improve survival over DPP4i in patients with cirrhosis and diabetes: Study Medha Baranwal20 July 2021 11:45 AM ISTPatients with cirrhosis needing additional pharmacotherapy for diabetes beyond metformin experience increased survival with SGLT2i in relation to...
EMPEROR-Preserved confirms success of Empagliflozin in HFpEF Hina Zahid8 July 2021 9:45 AM ISTEmpagliflozin therapy with specific benefits in patients with heart failure and preserved ejection fraction (HFpEF) may finally be on its way as the...
SGLT2 inhibitors better than sulfonylureas for reducing deaths in type 2 diabetes: JAMA Medha Baranwal5 July 2021 11:45 AM ISTSt Louis, Missouri: The use of SGLT2 inhibitors may reduce the risk of all-cause mortality compared with sulfonylureas in patients with type 2...
SGLT2 inhibitors cause double weight loss than GLP-1 receptor agonists in diabetics: Study Hina Zahid3 July 2021 10:30 AM ISTAmong 72 patients, people using SGLT2 inhibitors experienced a median weight loss of more than 6 pounds, while those on GLP-1 receptor agonists lost a...
SGLT2 inhibitors may reduce risk of kidney stone formation in diabetics: Study Medha Baranwal30 Jun 2021 10:00 AM ISTDenmark: Initiation of treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2Is) may prevent incident and recurrent nephrolithiasis (kidney...
Sotagliflozin improves survival in patients of diabetes and worsening HF: Study Medha Baranwal22 Jun 2021 10:45 AM ISTUSA: The use of sotagliflozin increased days alive out of the hospital (DAOH) in type 2 diabetes (T2D) patients at high risk for recurrent...
High-dose SGLT2 inhibitors tied to superior blood sugar control in type 2 diabetes: Study Medha Baranwal21 Jun 2021 11:44 AM ISTChina: The use of clinically approved high-dose SGLT2 inhibitors may help in improving blood sugar levels, body weight and blood pressure in patients...
Dapagliflozin may Improve Diabetic Retinopathy, Finds Study MD Bureau10 May 2021 6:30 PM ISTDiabetic retinopathy (DR) is a leading cause of blindness and vision impairment. In a recent study presented at the Association for Research in Vision...
ADA 2020: Empagliflozin reduces insulin need in diabetes patients Medha Baranwal17 Jun 2020 8:36 PM ISTDelhi: Treatment with the SGLT2 inhibitor empagliflozin reduces dependency on insulin in patients with type 2 diabetes (T2D) and cardiovascular...
